Protagonist Therapeutics (PTGX) Stock Statistics & Valuation Metrics

Protagonist Therapeutics has a market cap or net worth of $9.37B. The enterprise value is $7.93B.

Market Cap

$9.37B

Enterprise Value

$7.93B

Protagonist Therapeutics has 64,708,280 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

64,708,280

Owned by Insiders

1.18%

Owned by Institutions

62.60%

Protagonist Therapeutics’s return on equity (ROE) is -0.21 and return on invested capital (ROIC) is -25.23%.

Return on Equity (ROE)

-0.21

Return on Assets (ROA)

-0.19

Return on Invested Capital (ROIC)

-25.23%

Return on Capital Employed (ROCE)

-0.25

Revenue Per Employee

326.35K

Profits Per Employee

-923.04K

Employee Count

141

Asset Turnover

0.07

Inventory Turnover

0.00

The current PE Ratio of Protagonist Therapeutics is 118.91. Protagonist Therapeutics’s PEG ratio is -0.14.

PE Ratio

118.91

PS Ratio

33.24

PB Ratio

11.35

Price to FCF

70.92

Price to Operating Cash Flow

72.80

PEG Ratio

-0.14

In the last 12 months, Protagonist Therapeutics had revenue of 46.02M and earned -130.15M in profits. Earnings per share was -2.05.

Revenue

46.02M

Gross Profit

44.79M

Operating Income

-158.13M

Pretax Income

-129.31M

Net Income

-130.15M

EBITDA

-128.03M

Earnings Per Share (EPS)

-2.05

In the last 12 months, operating cash flow was 131.20M and capital expenditures 975,000, giving a free cash flow of 132.17M billion.

Operating Cash Flow

131.20M

Free Cash Flow

132.17M

Free Cash Flow per Share

2.00

Protagonist Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

1.41%

Earnings Yield

0.87%

Beta

-0.10

52-Week Price Change

86.06%

50-Day Moving Average

142.95

200-Day Moving Average

116.96

Relative Strength Index (RSI)

57.91

Average Volume (3m)

645.07K

Protagonist Therapeutics upcoming earnings date is Nov 05, 2026, TBA (Not Confirmed).

Last Earnings Date

Aug 05, 2026

Next Earnings Date

Nov 05, 2026

Ex-Dividend Date

―

Protagonist Therapeutics as a current ratio of 12.71, with Debt / Equity ratio of 1.68%

Current Ratio

12.71

Quick Ratio

12.71

Debt to Market Cap

0.00

Net Debt to EBITDA

0.92

Interest Coverage Ratio

0.00

In the past 12 months, Protagonist Therapeutics has paid 838.00K in taxes.

Income Tax

838.00K

Effective Tax Rate

-0.01

Protagonist Therapeutics EV to EBITDA ratio is 104.36, with an EV/FCF ratio of 67.81.

EV to Sales

31.78

EV to EBITDA

104.36

EV to Free Cash Flow

67.81

EV to Operating Cash Flow

68.31

Protagonist Therapeutics has $782.58M in cash and marketable securities with $9.22M in debt, giving a net cash position of $773.36M billion.

Cash & Marketable Securities

$782.58M

Total Debt

$9.22M

Net Cash

$773.36M

Net Cash Per Share

$11.95

Tangible Book Value Per Share

$12.76

Gross margin is 99.86%, with operating margin of 20.69%, and net profit margin of 29.40%.

Gross Margin

99.86%

Operating Margin

20.69%

Pretax Margin

29.91%

Net Profit Margin

29.40%

EBITDA Margin

30.45%

EBIT Margin

29.91%

The average price target for Protagonist Therapeutics is $174.58, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

$174.58

Price Target Upside

20.53% Upside

Analyst Consensus

Strong Buy

Analyst Count

13

Revenue Growth Forecast

34.81%

EPS Growth Forecast

44.59%

Smart Score

9

AI Score

70